Get the Stockscreener App
4.47
3.46%
-0.16
After Hours:
4.45
-0.02
-0.45%
Curevac N V stock is traded at $4.47, with a volume of 852.30K.
It is down -3.46% in the last 24 hours and up +26.63% over the past month.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
See More
Previous Close:
$4.63
Open:
$4.7
24h Volume:
852.30K
Relative Volume:
1.30
Market Cap:
$1.01B
Revenue:
$596.48M
Net Income/Loss:
$123.72M
P/E Ratio:
8.151
EPS:
0.5484
Net Cash Flow:
$106.59M
1W Performance:
+9.29%
1M Performance:
+26.63%
6M Performance:
+55.75%
1Y Performance:
+18.57%
1-Day Range:
$4.43
$4.725
1-Week Range:
$4.11
$4.795
52-Week Range:
$2.37
$5.28
Curevac N V Stock (CVAC) Company Profile
Compare CVAC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVAC
Curevac N V
|
4.47 | 920.90M | 596.48M | 123.72M | 106.59M | 0.5484 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Curevac N V Stock (CVAC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-25-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-08-23 | Initiated | SVB Securities | Outperform |
| Jan-19-23 | Upgrade | UBS | Neutral → Buy |
| Jan-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jan-21-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-18-22 | Initiated | JMP Securities | Mkt Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Hold |
| Jun-17-21 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-26-21 | Resumed | Credit Suisse | Underperform |
| Apr-26-21 | Initiated | Guggenheim | Neutral |
| Dec-10-20 | Downgrade | Credit Suisse | Neutral → Underperform |
| Sep-08-20 | Initiated | BofA Securities | Buy |
| Sep-08-20 | Initiated | Credit Suisse | Neutral |
| Sep-08-20 | Initiated | Jefferies | Hold |
View All
Curevac N V Stock (CVAC) Latest News
CureVac (NASDAQ:CVAC) Given “Market Outperform” Rating at JMP Securities - Defense World
D. E. Shaw & Co. Inc. Purchases New Position in CureVac (NASDAQ:CVAC) - Defense World
CureVac (CVAC) Maintains Market Outperform Rating with Stable Price Target | CVAC Stock News - GuruFocus
CureVac stock maintains $10 target from JMP on GBM vaccine outlook - Investing.com UK
The Strong Earnings Posted By CureVac (NASDAQ:CVAC) Are A Good Indication Of The Strength Of The Business - simplywall.st
We Think CureVac's (NASDAQ:CVAC) Robust Earnings Are Conservative - Yahoo
CureVac First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
CureVac FY2025 EPS Forecast Increased by Leerink Partnrs - Defense World
BNP Paribas Financial Markets Takes $585,000 Position in CureVac (NASDAQ:CVAC) - Defense World
CureVac Announces Annual General Meeting for June 2025 - TipRanks
Earnings Beat: CureVac N.V. (NASDAQ:CVAC) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - Yahoo Finance
CureVac NV reports results for the quarter ended March 31Earnings Summary - TradingView
CureVac price target lowered to $2 from $2.50 at BofA - TipRanks
CureVac (CVAC): BofA Reduces Price Target Amidst Ongoing Challen - GuruFocus
CureVac N.V. Reports Q1 2025 Financial Results Amid Strategic Restructuring - TipRanks
CureVac Reports Q1 2025 Financial Results Amid Revenue Decline - TipRanks
CureVac (CVAC) Stock Rises After Q1 Update, Oncology Pipeline Gains Traction - Benzinga
CVAC Reduces Operating Loss in Q1 2025 Amid Strong Pipeline Progress | CVAC Stock News - GuruFocus
CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates - ACCESS Newswire
CureVac Secures Major FDA Win for Cancer Drug While Patent Battle Against BioNTech Heats Up - Stock Titan
Curevac Q1 Revenue Eur 900 Thousand - marketscreener.com
CureVac granted favorable decision by European Patent Office vs. BioNTech - TipRanks
CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE | CVAC Stock News - GuruFocus
CureVac Secures Critical Second Patent Win vs BioNTechJuly Court Showdown Set for mRNA Rights - Stock Titan
CureVac Secures Key Patent Victory in Litigation with BioNTech - TipRanks
Barclays PLC Has $118,000 Stake in CureVac (NASDAQ:CVAC) - Defense World
CureVac (CVAC) to Release Earnings on Thursday - Defense World
Analysts Offer Valuable Insight On CureVac N.V (CVAC) - Stocksregister
CureVac (NASDAQ:CVAC) Shares Gap Up – Should You Buy? - Defense World
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK - ACCESS Newswire
Geode Capital Management LLC Acquires 22,491 Shares of CureVac (NASDAQ:CVAC) - Defense World
UBS Group Lowers CureVac (NASDAQ:CVAC) Price Target to $12.00 - Defense World
CVAC (CureVac N.V) has impressive results - uspostnews.com
CureVac N.V. (NASDAQ:CVAC) Shares Fly 31% But Investors Aren't Buying For Growth - simplywall.st
Legal & General Group Plc Has $359,000 Holdings in CureVac (NASDAQ:CVAC) - Defense World
Understanding the Risks of Investing in CureVac N.V (CVAC) - knoxdaily.com
CureVac (CVAC) Target Price Reduced by UBS Analyst | CVAC Stock News - GuruFocus
UBS Trims Price Target on CureVac to $12 From $13, Maintains Buy Rating - marketscreener.com
CureVac's CVnCoV Phase 2b/3 Study Data Published in Preprints with The Lancet - ACCESS Newswire
CureVac N.V (CVAC) Stock: Navigating a Year of Stock Volatility - investchronicle.com
CureVac (NASDAQ:CVAC) Shares Gap Up – Here’s Why - Defense World
Can you still get a good price for CureVac N.V (CVAC) Shares at this point? - uspostnews.com
CureVac (CVAC) to Release Quarterly Earnings on Wednesday - Defense World
CureVac Among 3 Promising Penny Stocks To Watch - Yahoo Finance
CureVac (NASDAQ:CVAC) Trading Up 7.5% – Should You Buy? - Defense World
CureVac N.V. (NASDAQ:CVAC) Q4 2024 Earnings Call Transcript - Insider Monkey
CureVac N.V. Earnings Call: Financial Strength Amid Challenges - TipRanks
CureVac Stock Declines On Weaker-Than-Expected Q4 Revenue: Retail’s On Wait-And-Watch Mode - MSN
CureVac NV earnings beat by €0.06, revenue topped estimates - Investing.com South Africa
CureVac N.V. Reports Earnings Results for the Full Year Ended December 31, 2024 - marketscreener.com
CureVac: 2025 will be less costly - marketscreener.com
Curevac N V Stock (CVAC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):